Trial Profile

A Multicentric, Exploratory, Non-randomised, Non-controlled, Prospective, Open-label Phase II Study Evaluating Safety and Efficacy of IBU, G-CSF and Plerixafor as Stem Cell Mobilization Regimen in Patients Affected by X-CGD

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 09 Oct 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ibuprofen (Primary) ; Lenograstim (Primary) ; Pantoprazole (Primary) ; Plerixafor (Primary)
Indications Chronic granulomatous disease; Stem cell mobilisation
Focus Adverse reactions; Therapeutic Use
Acronyms XCGD-MOBI

18 Sep 2025 Planned End Date changed from 18 Jul 2023 to 18 Jul 2026.
27 Oct 2022 Planned End Date changed from 1 Aug 2018 to 18 Jul 2023.
27 Oct 2022 Planned primary completion date changed from 1 Sep 2017 to 13 Jul 2023.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com